SEP-363856: all 30 studies that test it

Page 1 of 1. Open to participants first (4), then studies with results posted, then the rest; newest registration first within each.

• A Trial of the Safety and Tolerability of SEP-363856 in Adults With Generalized Anxiety DisorderRecruitingNCT07786454Phase 3
• A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety DisorderRecruitingNCT07767903Phase 3
• A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety DisorderRecruitingNCT07759128Phase 3
• A Long-term Administration Trial of SEP-363856 in Patients With SchizophreniaRecruitingNCT07225712Phase 3
• An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic MedicationCompletedNCT05741528Phase 3Results posted
• A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic MedicationCompletedNCT05628103Phase 3Results posted
• A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.CompletedNCT04115319Phase 3Results posted
• A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With SchizophreniaCompletedNCT04092686Phase 3Results posted
• A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With SchizophreniaCompletedNCT04072354Phase 3Results posted
• A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) ImagingCompletedNCT04038957Phase 1Results posted
• An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With SchizophreniaCompletedNCT02970929Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With SchizophreniaCompletedNCT02969382Phase 2Results posted
• A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease PsychosisCompletedNCT02969369Phase 2Results posted
• A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With SchizophreniaActive, not recruitingNCT06894212Phase 3
• A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With SchizophreniaCompletedNCT05848700Phase 1
• A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety DisorderCompletedNCT05729373Phase 2/3
• A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive DisorderCompletedNCT05593029Phase 2
• A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With SchizophreniaCompletedNCT05542264Phase 1
• A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With SchizophreniaCompletedNCT05463770Phase 1
• A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) StandardCompletedNCT05402111Phase 1
• A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in JapanTerminatedNCT05359081Phase 3
• This is a Study to Determine the Effect of Multiple Doses of an Investigational Drug, Taken by Mouth, in People With Narcolepsy-cataplexy. Accepting Both Males and Females Ages of 18 Years to 55 Years. This Study Will be Conducted in the US and Will Require Approximately 13 Weeks Participation.CompletedNCT05015673Phase 1
• A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia.CompletedNCT04865835Phase 1
• A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension PhaseTerminatedNCT04825860Phase 2/3
• A Clinical Study to Investigate the Effect of an Investigational Drug on Electrocardiogram Intervals in Adults With Schizophrenia.CompletedNCT04369391Phase 1
• Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With SchizophreniaCompletedNCT04325737Phase 1
• A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With SchizophreniaTerminatedNCT04109950Phase 3
• Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia in 2 Parts (Part 1 and 2).CompletedNCT03370640Phase 1
• Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With SchizophreniaCompletedNCT01994473Phase 1
• Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype CharacteristicsCompletedNCT01972711Phase 1

← SEP-363856 overview